Total
0
Shares
Bod Australia (ASX:BOD) - CEO, Jo Patterson
CEO, Jo Patterson
Source: Jo Patterson
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medicinal cannabis company Bod Australia (BDA) has launched nine hemp-based products in collaboration with Swisse Wellness
  • More than 2000 leading retailers such as Coles, Priceline and Chemist Warehouse will receive these products
  • This launch marks the first hemp-based range for Swisse in Australia
  • The range is primarily made-up of skincare products, but soft gel caps containing hemp seed oil will also be launched
  • Bod’s share price is up a steady 21.4 per cent and shares are trading for 17 cents each

Medicinal cannabis company Bod Australia (BDA) has launched nine hemp-based products in collaboration with Swisse Wellness.

More than 2000 stores will receive these products and they will initially be available in leading retailers such as Coles, Priceline, and Chemist Warehouse.

“Launching nine products with such as recognised and trusted brand in Swisse is game-changing for Bod,” CEO Jo Patterson said.

“We anticipate considerable consumer uptake once stock is available for purchase. We look forward to providing regular updates to shareholders as sales build,” she added.

Following a partnership that Bod secured with Swisse’s parent company, Health and Happiness Group, in 2019, this launch marks the first of the Swisse hemp-based range in Australia.

The range is primarily made-up of skincare products, but soft gel caps containing hemp seed oil will also be launched.

Initial interest from the large retail groups has already been encouraging.

“Swisse’s Hemp product rollout is a strategic move for the brand as we focus on offering innovative wellness solutions that respond to consumer shifts and growing demand,” Swisse Managing Director Nick Mann commented.

“We are preparing our business for the legalisation of CBD in Australia, so we can take advantage of the market with product innovation in partnership with Bod,” he added.

Swisse will undertake the sales and marketing campaigns, as well as in-store promotions.

To broaden its footprint and progress into the international market, Bod and Health and Happiness will continue working together to create new hemp-based products.

Bod’s share price is up a steady 21.4 per cent and shares are trading for 17 cents each at 2:38 pm AEDT.

BDA by the numbers
More From The Market Herald
Amplia Therapeutics - CEO and MD, John Lambert

" Amplia Therapeutics (ASX:ATX) granted $2.1 million R&D cash flow loan

Amplia Therapeutics (ATX) has been granted a $2.1 million Research and Development (R&D) cash flow loan.
Creso Pharma (ASX:CPH) - Creso Pharma

" Creso Pharma’s (ASX:CPH) Halucenex secures Dealer’s Licence amendment

Halucenex Life Sciences, a subsidiary of Creso Pharma (CPH), has secured an amendment to its Controlled Drugs and Substances Dealer’s Licence.

" Immutep (IMM) treats first five patients in solid tumour study

Immutep (IMM) has treated five patients in its study evaluating eftilagimod (efti) alpha in conjunction with standard of care chemotherapy.
Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu

" Zelira Therapeutics (ASX:ZLD) granted ethics approval for chronic pain trial

Zelira Therapeutics (ZLD) has received ethics approval for its Phase 2a clinical trial for chronic pain.